On the HCPLive Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.
June 12th 2024
Findings from a pair of phase 2a trials showed combination imdusiran and IFN or VTP-300 with standard-of-care NA therapy led to meaningful and sustained reductions in HBsAg levels.
Hepatology Month in Review: January 2024
February 3rd 2024The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.
Pregnant Women in Rural Regions Face Greater HCV, Preterm Birth Burden
January 26th 2024Results showed a 12% incidence of HCV in pregnancy with a preterm birth rate nearly double the national average, although no statistically significant difference in preterm birth rates was observed between HCV-positive and HCV-negative patients.
Achieving SVR Reduces Risk of Cardiovascular Events in Patients with HCV
January 23rd 2024Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.
Hepatitis C Genotype, Cirrhosis, Gender May Impact Effectiveness of DAA Therapy
January 11th 2024Although the overall response rate among the cohort was 96.4%, this figure dropped as low as 66.7% when accounting for male gender, GT3 infection, cirrhosis, obesity, and non-response to previous therapy.
Hepatitis B Markers, Reactivation Do Not Impact Effectiveness of DAA Therapy for HCV
January 10th 2024Response to direct-acting antiviral therapy was similar between patients with and without HBV coinfection, with most patients completing the planned course of treatment and achieving SVR, even in the case of HBV reactivation.
Increases in HCV-Related Liver Cancer Incidence, Mortality Suggest Rising Global Health Burden
January 9th 2024Investigators examined data from the Global Burden of Disease, Injuries, and Risk Factors study 2019 to describe the global, regional, and national burden of liver cancer due to hepatitis C since 1990.
Direct-Acting Antivirals Reduce Iron Parameters in Patients with HCV, Hyperferritinemia
January 2nd 2024Statistically significant reductions in serum ferritin, transferrin saturation index, and iron levels were observed after treatment, with hyperferritinemia eradicated in nearly all patients treated with DAAs achieving SVR.